myNEO Therapeutics
Lien Lybaert has a strong background in pharmaceutical sciences and immunotherapy research. Currently, Lien serves as the Chief Development Officer at myNEO Therapeutics, leading the development of groundbreaking immunotherapies to combat cancer. Prior to this role, Lien held positions at Persomed, Vrije Universiteit Brussel, Xedev, 2 Bridge CVBA, and Universiteit Gent, where they contributed significantly to various research and project management initiatives in the field of oncoimmunology. With a Master's degree in Pharmaceutical Sciences and extensive experience in both academia and industry, Lien brings a wealth of knowledge and expertise to the biopharmaceutical sector.
This person is not in any teams
myNEO Therapeutics
myNEO Therapeutics is a distinguished biopharmaceutical powerhouse, dedicated to pioneer breakthrough immunotherapies to fight cancer. myNEO Therapeutics is leveraging its ImmunoEngine discovery platform to tap into novel promising tumor targets found in the dark genome – named camyotopes™ – which have the potential to unlock immunotherapy for large patient populations who currently do not respond. In parallel, the service angle of myNEO Therapeutics, myNEO Intelligence, assists biopharma companies in transforming their decision-making process from trial & error to data-driven decisions using an AI-powered platform. Deriving insights from its expansive library of clinical and molecular data, myNEO Intelligence maps the molecular profiling of cancer patients at an individual level and then correlates the different data points to make data-driven decisions across the drug development life cycle. myNEO Intelligence can identify novel targets and biomarkers, prioritize drug candidates and indications, stratify patient populations and predict treatment response.